Lacosamide

Vimpat (VIM-pat) is the brand name used in the United States and some other countries for the seizure medicine lacosamide (la-COS-a-mide).

In the United States, the Food and Drug Administration (FDA) approved lacosamide in 2008 to be used together with other seizure medicines (called add-on or adjunctive seizure medicine) in adults with partial-onset epilepsy. (Partial onset epilepsy means that seizures start in a part of the brain and may stay in that area, or spread to other areas.)

In August 2014, Vimpat was approved for use as monotherapy in the treatment of partial-onset seizures in adults with epilepsy. 

Vimpat
Tablet
Vimpat 50mg

50-mg (pink)

Vimpat 100mg

100-mg (dark yellow)

Vimpat 150mg

150-mg (salmon)

Vimpat 200mg

200-mg (blue) film-coated tablets

Liquid Injection

200-mg in each-20 mL single-use vial for intravenous use

Indications

VIMPAT (lacosamide) tablets are indicated as monotherapy or adjunctive therapy in the treatment of partial-onset (focal) seizures in patients with epilepsy aged 17 years and older. 

Use can be in partial-onset seizures with or without secondary generalization to tonic-clonic (previously called grand mal) seizures.

VIMPAT (lacosamide) injection for intravenous use is indicated as add-on therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible, for example, due to illness or a surgical procedure.

Forms

Vimpat is marketed in the United States by UCB Pharma, Inc. The name or appearance may differ in other places. The dose (measured in milligrams, abbreviated "mg") will usually be the same. These descriptions apply to the U.S. versions:

Dosing

Please see package insert.

How to take and store Lacosamide?

Please see package insert.

Missed Doses

Please see package insert.

Mechanisms of actions of Lacosamide

Similar to almost every other seizure medication currently approved, the mechanism of the antiseizure effect of lacosamide is not fully understood. It is believed that lacosamide impacts its antiseizure effect by enhancing sodium channel slow inactivation. Thus, lacosamide would have a similar yet distinct mechanism to other seizure medications, such as phenytoin or carbamazepine.

Clinical Pharmacology of Lacosamide

The process of absorbing, digesting, and getting rid of a medicine or food is called metabolism. The way the body metabolizes a particular medicine affects how often it must be taken. It also determines if it will interact with other medicines or be affected by conditions such as liver disease.

After taking Vimpat tablets, peak blood levels are reached in 1-4 hours. The amount of time it takes for the blood level to fall by half is generally around 13 hours. Vimpat is usually taken two times a day. Vimpat is partially metabolized in the liver and it is then cleared from the body in the urine by the kidneys. People with poor kidney function usually need to take less Vimpat and may take it less often, because it stays in their body longer.

Efficacy of Lacosamide

Please see package insert.

Common side effects of Lacosamide

Please see package insert.

Lacosamide Contraindications

Please see package insert.

Lacosamide Interactions with other medications

Please see package insert.

Lacosamide effects on Children

Please see package insert.

Lacosamide and Pregnancy

Please see package insert.

Lacosamide effects on Seniors

Please see package insert.

Lacosamide Dosing and titration

See package insert.

Lacosamide Package insert

In the United States, companies that manufacture medicines are required to publish certain kinds of information about each product. This document is commonly known as a “package insert” because it is usually included with each package of the medicine.

You can also read these documents (also called "prescribing information") online. The U.S. package insert for Vimpat (lacosamide) is found at:

Some of the information may differ in other countries.

Learn how to read a package insert here.

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline